-

Model N Announces State of Revenue Webinars for Life Sciences and High-Tech Industries

Model N releases yearly report coupled with webinar to discuss results, market and innovation trends directly impacting industries

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, today announced its upcoming State of Revenue webinars on February 7 at 11 a.m. ET and 1 p.m. ET. The live webinars will coincide with the release of the company’s fifth annual State of Revenue Report.

What:

Be the first to hear from Model N’s industry experts as they present key insights from the 2023 State of Revenue Report. The survey covers insights from executives responsible for optimizing revenue and ensuring compliance at large high-tech, semiconductor manufacturing, pharmaceutical and medical technology companies. Speakers will discuss:

  • How revenue management teams are evolving to capitalize on new opportunities and overcome the macroeconomic trends that make revenue optimization so difficult.
  • Ways that life sciences and high-tech organizations can leverage technology to support revenue management, channel, and compliance activities.

Who:

  • Jesse Mendelsohn, SVP of Center of Excellence at Model N
  • Gloria Kee, Vice President of Product Management at Model N
  • Kyle Forcier, Sr. Director of Product Marketing at Model N
  • Chris Shrope, Associate Director of Product Marketing at Model N
  • Adam Steele, Marketing Director at Model N

When:

February 7, 2023, 11 a.m. ET (Life Sciences) and 1 p.m. ET (High Tech)

Where:

Register for the Life Sciences event here.

Register for the High Tech event here.

About Model N

Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.

Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit www.modeln.com.

Contacts

Public Relations
BLASTmedia
modeln@blastmedia.com

Model N, Inc.

NYSE:MODN

Release Versions

Contacts

Public Relations
BLASTmedia
modeln@blastmedia.com

Social Media Profiles
More News From Model N, Inc.

Vista Equity Partners Completes Acquisition of Model N

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced the completion of its acquisition by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses, for $30.00 per share in cash in a transaction that values the Company at approximately $1.25 billion. With the completion of the transaction, Model...

Model N Launches Channel Collaboration to Strengthen Visibility for High-Tech Manufacturers and Their Channel Partners

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), the leader in revenue optimization and compliance today announced the launch of Channel Collaboration, a new self-service portal for high-tech manufacturers and their channel partners. Channel Collaboration provides high-tech manufacturers and their partners real-time visibility into channel data, enabling faster and more informed business decisions while maintaining channel compliance. "Channel collaboration plays a pivotal role in the...

Model N Responds to Mounting Regulatory Pharma Pressures with Innovations that Ensure Compliance and Optimize Revenue

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), the leader in revenue optimization and compliance today announced new product innovations geared towards the increasingly complex regulatory environment for global pharma manufacturers. Model N’s latest product enhancements relating to 340B, the Inflation Reduction Act (IRA), and global pricing help pharma manufacturers effectively manage duplicate discounts and maintain compliance with evolving U.S. and international regulations. Contin...
Back to Newsroom